Drug Delivery: Transdermal Devices
For inquiries about purchasing this report or becoming a subscriber, please contact us at [email protected].
In 2021, global sales of transdermal patch products targeting the conditions covered by this analysis totaled nearly $4.9bn, with pain management products accounting for the most sales, followed by neurological disorder management products, cardiovascular disease (CVD)-related products, and hormone replacement therapy (HRT)-related products. Market drivers include the increasing prevalence of CVD, neurological disorders, osteoporosis, menopause, and chronic pain as the population ages; as well as improved patient compliance with patch-based pharmacology compared to oral medication. Limiters include declines in mature market segments, strong competition from oral medications, and generic erosion as brand manufacturers experience patent expiry. This analysis provides a discussion of the sales, competitors, drivers, and limiters of the transdermal drug delivery devices market in the areas of CVD (eg angina pectoris and hypertension), neurological disorders (eg ADHD, major depressive disorder, Alzheimer’s disease, and Parkinson’s disease), HRT (eg menopause and osteoporosis treatment), and pain management (eg fentanyl- and lidocaine-based chronic pain treatment). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.